Oruka Therapeutics, Inc. ORKA Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment

Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment at other companies

PopularBPOP

$1.82M+3.1%

NovaGold ResourcesNG

$64.9M—

Construction PartnersROAD

$51.46M-78.2%

ALH

Alliance Laundry Holdings Inc.ALH

$0—

KEE

Keel Infrastructure Corp. Common StockKEEL

$89.86M+22.9%

WingstopWING

$0—

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueNewIssues.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment?: Oruka Therapeutics, Inc. (ORKA) reported issuance of common stock in connection with the spin-off and reclassification of net parent investment of $38.9M in Q1 2026.